← Back to Search

Behavioural Intervention

Constipation Treatment for Chronic Kidney Disease

N/A
Recruiting
Research Sponsored by University of Tennessee
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Functional or opioid-induced constipation based on the Rome IV criteria
CKD stages G3-G5 without kidney replacement therapy with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2 calculated using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) 2021 creatinine equation
Must not have
Galactosemia
History of gastrointestinal surgery except appendectomy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from enrollment to the end of follow-up at 6 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to study the effects of constipation treatment on patients with chronic kidney disease. Researchers want to see if treating constipation can improve kidney and heart health outcomes and if it has any impact on

Who is the study for?
This trial is for adults over 18 with chronic kidney disease stages G3-G5 who are not on dialysis, have an eGFR under 60 mL/min/1.73m2, and suffer from functional or opioid-induced constipation. Participants must stop taking laxatives a week before the study but can use a rescue tablet if needed. Women must test negative for pregnancy unless postmenopausal or surgically sterile.
What is being tested?
The trial is exploring how treating constipation affects people with chronic kidney disease (CKD). It will look at whether this treatment can improve clinical outcomes and influence biochemical and microbiological parameters in patients with CKD who also experience constipation.
What are the potential side effects?
While specific side effects are not listed, typical reactions to constipation treatments may include abdominal pain, bloating, diarrhea, nausea, and sometimes electrolyte imbalances which could be significant in patients with CKD.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have constipation as defined by specific medical criteria.
Select...
My kidney function is reduced (eGFR <60) and I am not on dialysis.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have galactosemia.
Select...
I have had surgery on my digestive system, but not for appendicitis.
Select...
I haven't had major surgery in the last month and don't plan any during the study, except for dialysis access surgery.
Select...
I have a history of irritable bowel syndrome, inflammatory bowel disease, or Clostridium difficile infection.
Select...
I am currently on dialysis.
Select...
I have a working kidney transplant.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from enrollment to the end of follow-up at 6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and from enrollment to the end of follow-up at 6 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The feasibility of delivering the proposed interventions and performing the proposed examinations, assessed based on the adherence to prescribed protocol
Secondary study objectives
Changes in constipation symptoms
Changes in microbial parameters
Changes in plasma C-reactive protein
+7 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Constipation treatmentExperimental Treatment1 Intervention
A 4-week intervention of constipation treatment with lactulose
Group II: ControlActive Control1 Intervention
No constipation treatment except bisacodyl rescue therapy

Find a Location

Who is running the clinical trial?

University of TennesseeLead Sponsor
195 Previous Clinical Trials
144,565 Total Patients Enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,443 Previous Clinical Trials
4,331,087 Total Patients Enrolled
9 Trials studying Constipation
17,145 Patients Enrolled for Constipation
University of FloridaOTHER
1,397 Previous Clinical Trials
767,020 Total Patients Enrolled
1 Trials studying Constipation
35 Patients Enrolled for Constipation
~15 spots leftby Jun 2025